FEB 0 9 2004 BY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Milton D. GOLDENBERG

Title:

METHOD AND KIT FOR IMAGING AND TREATING ORGANS AND TISSUES

Appl. No.:

10/002,211

Filing Date:

12/05/2001

Examiner:

Unassigned

FEB 1 8 2004
TECHNOLOGY CENTER R3700

Art Unit:

3763

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

02/12/2004 SSITHIB1 00000066 10002211

01 FC:1806

180.00 OP

BEST AVAILABLE COPY



f

## RELEVANCE OF EACH DOCUMENT

The documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding European applications, EP 03 07 6875 and EP 03 07 6876. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of each Partial European Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEB 1 8 2004

FEE

**TECHNOLOGY CENTER R3700** 

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Feb. 9, 2004

FOLEY & LARDNER

Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

By

Stephen B. Maebius Attorney for Applicant Registration No. 35,264

BEST AVAILABLE COPY

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known 10/002,211 INFORMATION DISCLOSURE **Application Number** 12/05/2001 FEB 0 9 200V STATEMENT BY APPLICANT Filing Date David M. GOLDENBERG First Named Inventor Group Art Unit 3763 (use as many sheets as necessary) **Examiner Name** <u>Unassigne</u>d CRADEMAR Attorney Docket Number 018733-1066 of 2 Sheet

	U.S. PATENT DOCUMENTS								
Examiner Initials*	0.1-	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
	B1	4,036,945 A 4,331,647 A		HABER	07-19-1977				
	B2			GOLDENBERG	05-25-1982				
	В3	4,444,744	А	GOLDENBERG	04-24-1984				
	В4	4,735,210	А	GOLDENBERG	04-05-1988				
	B5	5,101,827	A	GOLDENBERG	04-07-1992				
	B6	5,144,007	A	PFAHL	09-01-1992				
	В7	5,152,980	А	STROM et al.	10-06-1992				

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Kind Code⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>		
	В8	EΡ	0 217 992	А	BETH ISRAEL HOSPITAL	04-15-1987				
	В9	EΡ	0 274 394	А	ONCOGEN	07-13-1988				
	B10	EP	0 330 201	А	NEORX CORPORATION	08-30-1989				
	B11	wo	83/04313	А	UNIV CALIFORNIA	12-08-1983				
	B12	wo	89/07601	A	TAN KIM SZE	08-24-1989				
	B13	wo	91/16069	А	US HEALTH	10-31-1991				
	B14	wo	93/13805	А	BAGSHAWE	07-22-1993				
	B15	wo	94/10202	А	GENENTECH INC.	05-11-1994				
						BEST AVAI	LABLE COF	Y		

Examiner	Date	
Signature	Consi	idered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B	/PTO	Complete if Known				
	INFORMATION DIS	SCLO	SURE	Application Number	10/002,211			
	STATEMENT BY A	<b>\PPLI</b>	CANT	Filing Date	12/05/2001	TPE		
				First Named Inventor	David M. GOLDENI	BER		
				Group Art Unit	3763	/		
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned	- 0 0 2004 iv		
Sheet	2	of	2	Attorney Docket Number	018733-1066	FEB 0 9 2004 B		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
	B16	BOSSLET et al., "Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA)," <u>International Journal of Cancer – Journal International Du Cancer</u> , July 15, 1985, pp. 75-84, Vol. 36, No. 1
	B17	DELAND et al., "Axillary lumphoscintigraphy by radioimmunodetection of carnioembryonic antigen in breast cancer," <u>Journal of Nuclear Medicine</u> , 1979, pp. 1243-1250, Vol. 20, No. 12
	B18	DILHUYDY et al., "Three-dimensional imaging of duel isotope data-sets in a case of acute myocardial infarction," <u>British Journal of Radiology 1992 United Kingdom</u> , March 1992, pp. 273-278, Vol. 65, No. 771
	B19	DUNCKER et al., "Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer," <u>J. Nucl. Med.</u> , 1990, pp. 1450-1455, Vol. 31, No. 9
	B20	MASUJIMA et al., "Biological component microanalysis by laser photoacoustic imaging immunoassay," <u>Chemical and Pharmaceutical Bulletin (Tokyo)</u> , 1989, pp. 1123-1125, Vol. 37, No. 4
	B21	RESKE et al., "Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lumphoma, " <u>Lancet</u> , 1989, pp. 299-301, Vol. 1, No. 8633
	B22	SHARKEY et al., "Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans," <u>Cancer Research</u> , 1990, pp. 2823-2831, Vol. 50, No. 9
	B23	SIEGLE et al., "Development of a model using polypeptide anitobodies for scintigraphy of the pancreas," <u>Investigative</u> Radiology, September 1980, pp. 457-461, Vol. 15, No. 5
	B24	SIGNORE et al., "A radiopharmaceutical for imaging areas of lymphocytic infiltration: lodine-123 interleukin-2: Labelling procedure and animal studies," <u>Nuclear Medicine Communications</u> , October 1992, pp. 713-722, Vol. 13, No. 10
	B25	SIGNORE et al., "The in vivo visualization of insulitis. A new marker of prediabetes," <u>Advances in Experimental Medicine and Biology</u> , 1988, pp. 119-125, Vol. 246
•	B26	TAKEDA et al., "Radioimmunolocalization of the monoclonal antibody J28 in early transformation stages in N-nitrosobis(2-hydroxypropyl)amine-induced pancreatic tumors in the Syrian golden hamster," <u>Journal of Cancer Research and Clinical Oncology</u> , 1992, pp. 377-385, Vol. 118, No. 5
	B27	VOLPINI et al., "Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization," <u>The American Journal of Cardiology</u> , January 1, 1989, pp. 7-13, Vol. 63, No. 1
		REST AVAILABLE COPY

Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.